demonstrated suggested inconclusive safety concern ongoing study display ongoing demontrated benefit only observational study
COVID-19 severe or critically
COVID-19 prophylaxis (excluding children)
Non replicating viral vector Pitisuttithum
CanSino (Convidecia) NCT04540419 CanSino phase 2 ... Fengcai Li J CanSino phase 3
Covishield (Oxford/AZ formulation) Kulkarni
Janssen AD26 vaccine (JNJ-78436735) HORIZON 1 MixNMatch Study Pawlowski EPIPHARE ... Sisonke 2 ... Sisonke study ... Sadoff Husby ... ENSEMBLE ... Reindl-Schwaighofer Botton ...
Sputnik V (Gam-COVID-Vac) RESIST ... Rearte Nabirova
Vaxzevria (AstraZeneca Oxford - ChAdOx1 nCoV-19) Burn ... ComFluCOV ... Hippisley-Cox Patone Folegatti Bernal ... Simpson ... AstraZeneca Oxford pooled analysis ... ChAdOx1 phase 3 ... Pottegard Sultan Husby ... Rearte John Bonelli COV005 Bernal Com-COV2 Kanokudom Com-COV Asano AstraZeneca phase 3 US ... AstraZeneca phase 3 US ... Scotland cohort Edward ... Nguyen EPIPHARE ... Clemens Valim

6 studies excluded by filtering options 2

4830 NCT04276896, 0 2300excludednot a RCTrisk of bias not avaialble
4992 Candidate COVID-19 Vaccine (COV001), 2020 210excludedrisk of bias not avaialble
6444 Barrett, 2020 200excludedrisk of bias not avaialble
8160 Babamahmoodi, 2021 2990excludednot a RCTrisk of bias not avaialble
9070 Tobaiqy M, 2021 2320excludednot a RCTrisk of bias not avaialble
9376 Nanthapisal, 2022 210excludedrisk of bias not avaialble